Taicang, July 9, 2015 – Suzhou Connect Biopharmaceuticals announced today that it has received issuance of patent No. ZL201310433018.6 from the State Intellectual Property Office (SIPO) of China. The patent covers composition of matter of the company’s investigational drug CBP-307 currently in Phase I clinical trial, with a patent term extending to September 2033.

About CBP-307

CBP-307 is a novel second generation modulator of the sphingosine-1-phosphate 1 receptor (S1P1), a G-protein coupled receptor (GPCR) that plays a central role in regulating T cell movement. CBP-307 is being developed as a treatment for a variety of autoimmune diseases, including multiple sclerosis (MS), psoriasis, and inflammatory bowel disease (IBD). The Phase I trial is a randomized, double-blind, placebo-controlled study in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug. Completion of the trial is expected later this year.

“We are delighted that the SIPO has issued this composition of matter patent, which provides us exclusivity of CBP-307 until at least 2033,” said Dr. Zheng Wei, Co-founder and CEO of Connect Biopharma. “This insurance is important for our global IP strategy around this key clinical asset, and we continue to prosecute multiple pending applications in China and all key jurisdictions including the United States, Europe and Japan.”

About Suzhou Connect Biopharmaceuticals

Founded in 2012, Suzhou Connect Biopharmaceuticals discovers and develops novel immune modulators for the treatment of autoimmune diseases and inflammation. The company identifies and advances its drug candidates through internal discovery and in-licensing. Its lead program CBP-307 is an orally-active S1P1 agonist with best-in-class potential for the treatment of a range of autoimmune disorders including multiple sclerosis (MS), inflammatory bowel disease (IBD), and psoriasis. In addition to CBP-307, the company is advancing CBP-174, an in-licensed drug candidate for allergic inflammation; and CBP-201, an internally-discovered monoclonal antibody for the treatment of asthma and eczema.